NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

Rhea-AI Summary

NGM Biopharmaceuticals announces presentation of NGM707 clinical data at AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.

Poster Presentation Details:

Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation
Presenter: Judy Wang, M.D., Associate Director, Drug Development Unit, Sarah Cannon Research Institute and Florida Cancer Specialists
Abstract #: CT099
Poster Session: First-in-Human Phase I Clinical Trials 1
Location: Poster Section 48
Date and Time: Monday, April 8th; 1:30 – 5:00 pm PT

This presentation will provide more detailed findings from the Phase 1 Part 1b dose escalation cohort of the ongoing Phase 1/2 trial evaluating NGM707 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with advanced or metastatic solid tumors than as originally reported by NGM Bio in January 2024.

Title: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors
Presenter: Lisa Blum, Ph.D., Principal Scientist, NGM Bio
Abstract #: 3641
Poster Session: Biomarkers in Clinical Trials
Location: Poster Section 40
Date and Time: Monday, April 8th; 1:30 – 5:00 pm PT  

About NGM Biopharmaceuticals, Inc.

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. NGM Bio’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Visit us at www.ngmbio.com for more information.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Investor Contact:			Media Contact:
ir@ngmbio.com			media@ngmbio.com

What is the title of the first abstract presented at the AACR Annual Meeting?

The title of the first abstract is 'NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation.'

Who is the presenter of the first abstract at the AACR Annual Meeting?

Judy Wang, M.D., Associate Director, Drug Development Unit, Sarah Cannon Research Institute and Florida Cancer Specialists, is the presenter of the first abstract.

What is the title of the second abstract presented at the AACR Annual Meeting?

The title of the second abstract is 'Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors.'

Who is the presenter of the second abstract at the AACR Annual Meeting?

Lisa Blum, Ph.D., Principal Scientist at NGM Bio, is the presenter of the second abstract.

When and where will the poster presentation of the first abstract take place at the AACR Annual Meeting?

The poster presentation of the first abstract will take place on Monday, April 8th, from 1:30 – 5:00 pm PT at Poster Section 48.

What will the presentation of the first abstract focus on?

The presentation will provide more detailed findings from the Phase 1 Part 1b dose escalation cohort of the ongoing Phase 1/2 trial evaluating NGM707 in combination with KEYTRUDA® for the treatment of patients with advanced or metastatic solid tumors.

When and where will the poster presentation of the second abstract take place at the AACR Annual Meeting?

The poster presentation of the second abstract will take place on Monday, April 8th, from 1:30 – 5:00 pm PT at Poster Section 40.

Who is the target audience for NGM707 in the ongoing Phase 1/2 clinical trial?

The target audience for NGM707 in the ongoing Phase 1/2 clinical trial are patients with advanced or metastatic solid tumors.